Siglec receptors as new immune checkpoints in cancer
- PMID: 35948467
- DOI: 10.1016/j.mam.2022.101112
Siglec receptors as new immune checkpoints in cancer
Abstract
Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies has improved the treatment and prognosis of many patients. Nevertheless, most cancers are still resistant to currently approved cancer immunotherapies. New approaches and rational combinations are needed to overcome these resistances. There is emerging evidence that Siglec receptors could be regarded as new immune checkpoints and targets for cancer immunotherapy. In this review, we summarize the experimental evidence supporting Siglec receptors as new immune checkpoints in cancer and discuss their mechanisms of action, as well as current efforts to target Siglec receptors and their interactions with sialoglycan Siglec-ligands.
Keywords: Cancer immunotherapy; Immune checkpoint inhibitor; Innate immunity; Monoclonal antibodies; Sialic acid; Sialidase; T cells.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest H.L. received travel grants and consultant fees from BMS and Merck, Sharp and Dohme (MSD). H.L. received research support from BMS and Palleon Pharmaceuticals. H.L. is a scientific advisor of InterVenn and GlycoEra. H.L. is a co-founder of Singenavir Ltd.
Similar articles
-
The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.Expert Opin Ther Targets. 2019 Oct;23(10):839-853. doi: 10.1080/14728222.2019.1667977. Epub 2019 Sep 23. Expert Opin Ther Targets. 2019. PMID: 31524529 Review.
-
Targeting glyco-immune checkpoints for cancer therapy.Expert Opin Biol Ther. 2021 Aug;21(8):1063-1071. doi: 10.1080/14712598.2021.1882989. Epub 2021 Feb 8. Expert Opin Biol Ther. 2021. PMID: 33502268
-
Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108. Glycobiology. 2018. PMID: 29309569 Review.
-
Siglec Signaling in the Tumor Microenvironment.Front Immunol. 2021 Dec 13;12:790317. doi: 10.3389/fimmu.2021.790317. eCollection 2021. Front Immunol. 2021. PMID: 34966391 Free PMC article. Review.
-
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.Trends Cancer. 2024 Mar;10(3):230-241. doi: 10.1016/j.trecan.2023.11.009. Epub 2023 Dec 29. Trends Cancer. 2024. PMID: 38160071 Review.
Cited by
-
Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR.Front Immunol. 2025 May 13;16:1536868. doi: 10.3389/fimmu.2025.1536868. eCollection 2025. Front Immunol. 2025. PMID: 40433387 Free PMC article.
-
The Tumour Glyco-Code: Sialylation as a Mediator of Stromal Cell Immunosuppression in the Tumour Microenvironment.Eur J Immunol. 2025 Jul;55(7):e70000. doi: 10.1002/eji.70000. Eur J Immunol. 2025. PMID: 40667828 Free PMC article. Review.
-
Sialic acid in the regulation of blood cell production, differentiation and turnover.Immunology. 2024 Aug;172(4):517-532. doi: 10.1111/imm.13780. Epub 2024 Mar 19. Immunology. 2024. PMID: 38503445 Free PMC article. Review.
-
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells.Pharmaceutics. 2024 Jul 19;16(7):953. doi: 10.3390/pharmaceutics16070953. Pharmaceutics. 2024. PMID: 39065651 Free PMC article.
-
Elevated Siglec-7 expression correlates with adverse clinicopathological, immunological, and therapeutic response signatures in breast cancer patients.Front Immunol. 2025 Jun 6;16:1573365. doi: 10.3389/fimmu.2025.1573365. eCollection 2025. Front Immunol. 2025. PMID: 40547037 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
